Evidence mapPaperPMID 30333554Full record

ReviewActa pharmacologica Sinica2019

Translational potential of allosteric modulators targeting the cannabinoid CB

Dai Lu, Sri Sujana Immadi, Zhixing Wu, Debra A Kendall

Open access · bronzeAbstract readReview
In one paragraph

Review in Acta pharmacologica Sinica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Negative allosteric modulation of CBNeuropharmacology · 2024
    Article
  5. Review
  6. Acta pharmaceutica Sinica. B · 2024
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Zebrafish as an Animal Model in Cannabinoid Research.International journal of molecular sciences · 2023
    Review
  12. Review
  13. Negative allosteric modulation of CBPharmacological research · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Dai LuRangel College of Pharmacy, Texas A&M University, Kingsville, TX, 78363, USA. dlu@tamhsc.edu.
Sri Sujana ImmadiRangel College of Pharmacy, Texas A&M University, Kingsville, TX, 78363, USA.
Zhixing WuRangel College of Pharmacy, Texas A&M University, Kingsville, TX, 78363, USA.
Debra A KendallDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, 06269, USA.
Texas A&M University – Kingsville · USUniversity of Connecticut · US

Funding

NIDA NIH HHS R01 DA039942
6 · The paper itself

Abstract

The cannabinoid type-1 (CB

Indexed as

Allosteric RegulationAnimalsCannabinoid Receptor AgonistsCannabinoid Receptor AntagonistsHumansLigandsMolecular StructureReceptor, Cannabinoid, CB1Signal TransductionStructure-Activity RelationshipCannabinoid Receptor AgonistsCannabinoid Receptor AntagonistsLigandsReceptor, Cannabinoid, CB1allosteric modulatorbiased signalingcannabinoid CB1 receptordrug discoveryfunctional selectivityG-protein-coupled receptortherapeutic potential

Identifiers

PMID30333554
PMCPMC6460365
OpenAlexW2897453865

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.